Pharmaceuticals · Nasdaq Copenhagen
Novo Nordisk
Price data: TradingView widget below
Novo Nordisk (NOVO-B) — Novo Nordisk is a Danish pharmaceutical company known for diabetes and obesity treatments, including GLP-1 medicines such as Ozempic and Wegovy.
Why people search for it: Searched as Europe’s obesity/diabetes pharma leader — Ozempic/Wegovy keep the ticker in global headlines.
Loading chart…
Open NOVO-B chart in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
Loading chart…
📐 Technicals
Loading chart…
Indicator summary from TradingView (moving averages, oscillators). A mechanical signal, not advice.
Open technicals in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
📊 Fundamentals
Loading chart…
🏢 Company profile
Loading chart…
📰 Latest NOVO-B news
Loading chart…
🧩 What it is
Novo Nordisk is a Danish pharmaceutical company known for diabetes and obesity treatments, including GLP-1 medicines such as Ozempic and Wegovy.
⚡ Why it's interesting
It became one of Europe’s most valuable companies as demand for weight-loss and diabetes drugs surged worldwide, keeping NOVO-B in constant search interest.
⚠️ Key risks
Valuation prices in rapid growth; competition in GLP-1, supply constraints, pricing pressure and any safety headlines can move the stock sharply. Currency (DKK/EUR) matters for international investors.
👀 What to watch
GLP-1 sales, manufacturing capacity, rival trial data and US pricing/reimbursement news.
Written by the Hodlia.fi editorial team. Education only — not financial advice, no price predictions. Contains a TradingView affiliate link.
❓ Novo Nordisk FAQ
What is Novo Nordisk (NOVO-B)?
Novo Nordisk is a Danish pharmaceutical company known for diabetes and obesity treatments, including GLP-1 medicines such as Ozempic and Wegovy.
Why do people follow Novo Nordisk?
It became one of Europe’s most valuable companies as demand for weight-loss and diabetes drugs surged worldwide, keeping NOVO-B in constant search interest.
Why do people search for Novo Nordisk?
Searched as Europe’s obesity/diabetes pharma leader — Ozempic/Wegovy keep the ticker in global headlines.
What are the main risks of Novo Nordisk?
Valuation prices in rapid growth; competition in GLP-1, supply constraints, pricing pressure and any safety headlines can move the stock sharply. Currency (DKK/EUR) matters for international investors.
What should I watch with Novo Nordisk?
GLP-1 sales, manufacturing capacity, rival trial data and US pricing/reimbursement news.
Is Novo Nordisk a good investment?
Hodlia не надає інвестиційних порад. Чи підходить вам Novo Nordisk, залежить від ваших цілей, горизонту та того, яку втрату ви можете витримати. Окремі акції можуть сильно впасти навіть на спокійному ринку. Прочитайте ризики вище, порівняйте з диверсифікованою альтернативою та зверніться по незалежну пораду.